EU/3/09/652: Orphan designation for the treatment of cystic fibrosis


Table of contents


On 24 July 2009, orphan designation (EU/3/09/652) was granted by the European Commission to Interface International Consultancy Ltd, United Kingdom, for ciprofloxacin (liposomal) for the treatment of cystic fibrosis.

The sponsorship was transferred to Aradigm Limited, United Kingdom, in November 2016.

The sponsorship was transferred to Savara ApS, Denmark, in June 2020.

The sponsor’s address was updated in April 2022.

Key facts

Active substance
Intended use
Treatment of cystic fibrosis
Orphan designation status
EU designation number
Date of designation

Savara ApS
Tuborg Boulevard 12
2900 Hellerup
Tel: +45 7930 1417

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating